Pretreatment with Cilostazol Attenuates Carboplatin Induced Cytotoxicity and Genotoxicity in Bronchial Epithelial Cells (Beas-2B) and Human Blood Lymphocytes

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

Shokrzadeh Mohammad; Rahmati Mahboube; Gharehkhani Elahe; Zare Rouzbeh; Pourmohammadi Parsa; Aghajanshakeri Shaghayegh

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Journal of Mazandaran University of Medical Sciences Year:2023 | Volume: | Issue: Page(s): 24-36

Download Full-Text

Persian Verion

View:

Download:

Cites:

Information Journal Paper

Title

Pretreatment with Cilostazol Attenuates Carboplatin Induced Cytotoxicity and Genotoxicity in Bronchial Epithelial Cells (Beas-2B) and Human Blood Lymphocytes

Author(s)

Keywords

cilostazolQ4

carboplatinQ4

micronucleus assayQ4

cytotoxicityQ4

Abstract

Background and purpose: cilostazol is a prescription medication for intermittent claudication in patients with peripheral artery disease. Previous research has demonstrated that this 2-oxoquinoline derivative possesses antithrombotic, vasodilator, antimitogenic, and antioxidant effects. cilostazol exerts its products through the inhibition of PDE3 activity and the prevention of cAMP degradation. The present study aimed to examine the protective properties of cilostazol against carboplatin-induced cytotoxicity and genotoxicity in Beas-2B and human blood lymphocyte cells. Materials and methods: cells were pre-treated with different concentrations of cilostazol (5, 25, 50, and 100 μM) with carboplatin at an optimum cytotoxic dosage (9. 2 µM). The MTT and micronucleus assays were used to assess cytotoxicity and genotoxicity. Statistical analysis was performed using the one-way ANOVA in Prism Ver. 8 software. Results: The cytotoxic effect of carboplatin was dose-dependent, as evidenced by the 48h culture treatment with concentrations of 0. 3, 1, 3, 10, and 30 µM. Pre-treatment of cilostazol at 25, 50, and 100 µM with carboplatin at 9. 2 µM enhanced cell viability in Beas-2B cells compared to the carboplatin alone as positive control. Additionally, cilostazol at 50 and 100 µM showed its potent genoprotective effects via micronucleus assay against carboplatin at IC50 at blood lymphocyte cells. Conclusion: cilostazol provided conceivable protective effects by modulating cytotoxicity and genotoxicity induced by carboplatin in Beas-2B and human blood lymphocyte cells.

Cites